Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 19:21:200261.
doi: 10.1016/j.ijcrp.2024.200261. eCollection 2024 Jun.

Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database

Dimitrios Terentes-Printzios  1 , Ioanna Dima  1 , Panorios Benardos  2 , Panagiota Mitrou  3 , Konstantinos Mathioudakis  4 , Anastasios Tsolakidis  4 , Fotios Barkas  5 , Konstantinos Tsioufis  1 , Petros P Sfikakis  6 , Evangelos Liberopoulos  6 , Charalambos Vlachopoulos  1
Affiliations

Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database

Dimitrios Terentes-Printzios et al. Int J Cardiol Cardiovasc Risk Prev. .

Abstract

Background: Despite recent guidelines appropriate lipid-lowering treatment (LLT) remains suboptimal in everyday clinical practice.

Aims: We aimed to describe clinical practice of use of LLT for at least high CV risk populations in a Hellenic real-world setting and assess how this relates to the European Society of Cardiology treatment guidelines.

Methods: We analyzed data from a retrospective cohort study of the National Registry of patients with dyslipidemia between 1/7/2017 and 30/6/2019 who were at least of high CV risk and filled a dual or triple lipid-lowering treatment (dLLT, tLLT) prescription. The primary outcomes of interest of this analysis were to report on the patterns of LLT use in at least high CV risk patients.

Results: A total of 994,255 (45.4% of Greeks on LLT) were of at least high CV risk and 120,490 (5.5%) were on dLLT or tLLT. The percentage of patients with reported statin intolerance ranged from 2 to 10%. While persistence was reported to be satisfactory (>85% for both dLLT or tLLT), adherence was low (ranging between 14 and 34% for dLLT). In 6-month intervals, the percentage of patients achieving a low-density lipoprotein cholesterol (LDL-C) target below 100 md/dL ranged from 20% to 23% for dLLT and 34%-37% for tLLT.

Conclusions: The prevalence of at least high CV risk patients among patients receiving LLT in Greece is substantial. Despite the high persistence and probably due to the low adherence to treatment, LDL-C remains above targets in more than two thirds of patients.

Keywords: Cardiovascular risk; Dyslipidemia; Ezetimibe; Familial hypercholesterolaemia; LDL-Cholesterol; Lipid-lowering therapy’ statins; PCSK9 inhibitors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Number of at least high CV risk patients on dLTT and tLTT by 6-month period.
Fig. 2
Fig. 2
Percentage of patients on tLLT or single-pill combination dLLT with good persistence (panel A) and good adherence (panel B) to treatment.
Fig. 3
Fig. 3
Percentage of patients on dLLT achieving LDL-C targets based on LDL-C target <100 mg/dL (panel A) and LDL-C target <70 mg/dL (panel B).
Fig. 4
Fig. 4
Percentage of patients on tLLT achieving LDL-C targets based on LDL target <100 mg/dL (panel A) and LDL-C target <70 mg/dL (panel B).
figs1
figs1
figs2
figs2
See this image and copyright information in PMC

References

    1. Ray K.K., Molemans B., Schoonen W.M., Giovas P., Bray S., Kiru G., Murphy J., Banach M., De Servi S., Gaita D., Gouni-Berthold I., Hovingh G.K., Jozwiak J.J., Jukema J.W., Kiss R.G., Kownator S., Iversen H.K., Maher V., Masana L., Parkhomenko A., Peeters A., Clifford P., Raslova K., Siostrzonek P., Romeo S., Tousoulis D., Vlachopoulos C., Vrablik M., Catapano A.L., Poulter N.R. Study DV. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279–1289. - PubMed
    1. Barrios V., Soronen J., Carter A.M., Anastassopoulou A. Lipid management across Europe in the real-world setting: a rapid evidence review. Curr. Med. Res. Opin. 2021;37:2049–2059. - PubMed
    1. Liatis S., Dafoulas G.E., Kani C., Politi A., Litsa P., Sfikakis P.P., Makrilakis K. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res. Clin. Pract. 2016;118:162–167. - PubMed
    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O., Group E.S.C.S.D. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41:111–188. - PubMed
    1. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Z., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M.M., Vlachopoulos C., Wood D.A., Zamorano J.L., Cooney M.T., Group E.S.C.S.D. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 2016;37:2999–3058. - PubMed

LinkOut - more resources